Scitherm
Preclinical-stage startup developing thermogenesis-based therapeutic candidates for obesity and related metabolic diseases. Uses computational molecular design and enzymatic synthesis to create small-molecule thermogenics, and applies in-vitro and in-vivo assays including metagenomic analysis of adipocytes to evaluate lipid degradation and fat mass reduction. Focused on selecting a lead candidate for preclinical development and working with external partners and early-stage investors.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical thermogenic therapeutic candidates
Enzymatically synthesized, in-silico-designed small-molecule candidates intended to activate lipid degradation pathways and reduce fat mass; currently in preclinical selection and validation planning.
Preclinical thermogenic therapeutic candidates
Enzymatically synthesized, in-silico-designed small-molecule candidates intended to activate lipid degradation pathways and reduce fat mass; currently in preclinical selection and validation planning.
Expertise Areas
- Obesity and metabolic-disease therapeutic discovery
- Computational drug design and molecular modeling
- Medicinal chemistry and enzymatic synthesis
- Preclinical assay development and validation
Key Technologies
- Computational molecular modeling
- In-silico drug design
- Metagenomic analysis
- Enzymatic/biocatalytic synthesis
News & Updates
Company reports recent pre-seed funding to support candidate selection and preclinical advancement.
Lists an external partner organization as a collaborator for growth and support.
Company reports recent pre-seed funding to support candidate selection and preclinical advancement.
Lists an external partner organization as a collaborator for growth and support.